New Senior Executives appointed at Sanofi

SanofiSanofi (EURONEXT : SAN ; NYSE : SNY) announced the appointment of Greg Irace, currently President and CEO of Sanofi's US operations, to the newly created role of Senior Vice President, Global Services. In his new role, Greg will lead the Global Information Systems function, be responsible for shared support functions across all Sanofi businesses in North America and play a key role in the development of a global strategy for shared services. Greg will report to Jérôme Contamine, Executive Vice President, Chief Financial Officer, and will continue to be a member of the Global Management Committee. He will be based in Bridgewater, New Jersey.

Jérôme Contamine, Executive Vice President, Chief Financial Officer, Sanofi, commented: "The integration of Genzyme and Merial gives Sanofi the opportunity to create a platform of shared support functions to serve Sanofi's five North American businesses and its more than 20,000 employees. I am confident that Greg's dedication and the leadership he has shown in his previous roles will result in his leading this new organization to great success."

Anne C. Whitaker will join Sanofi as President, North America, Pharmaceuticals, effective September 1, 2011. She will report to Hanspeter Spek, President, Global Operations and will join the Global Management Committee. She will be based in Bridgewater, New Jersey.

Hanspeter Spek, President, Global Operations, Sanofi, declared: "The knowledge and experience Anne has gained through her previous roles in Sales, Marketing and Leadership Development in the Pharmaceutical industry, particularly in the United States, make her ideally suited to drive the renewed growth of our pharmaceutical operations in North America."

Anne joins Sanofi from GSK, where she was Senior Vice President and Business Unit Head, Cardiovascular, Metabolic and Urology, since 2009. Anne holds a Bachelors degree in Chemistry and Business Administration from the University of North Alabama. She began her career at Delta Communications and joined the Upjohn Company in 1991 as a metabolic disease specialist. She joined GSK in 1992 as a sales representative and held various positions in Sales and Training. In 2001, she became Vice President of Critical and Supportive Care, a Business Division based in Pennsylvania, before being appointed Senior Vice President of Leadership and Organization Development, based in London, England, from 2008 to 2009.

Greg Irace holds a B.S. in accounting from Albany State University. He began his career at Price Waterhouse in 1980 and received his CPA in 1982. He spent 11 years at Price Waterhouse becoming a Senior Audit Manager in 1988, and a Senior Manager in the Corporate Finance Department in 1989. In 1991, he joined Sterling Winthrop Inc. and became in 1993 Director of Financial Planning and Analysis, and then Chief Financial Officer of Sanofi's Pharmaceutical Operations in the United States in 1994. He has held his current responsibilities for the US operations since 2007.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Pfizer begins a Phase 1/2 study to evaluate respir…

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV i...

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study demonstrates new treatment for severe asthma

Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering ...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...